JY
ABEO icon

Jeff Yass’s Abeona Therapeutics ABEO Stock Holding History

Jeff Yass’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$805K Sell
130,300
-253,600
-66% -$1.39M ﹤0.01% 8766
2026
Q1 		$1.72M Buy
383,900
+174,000
+83% +$870K ﹤0.01% 6530
2025
Q4 		$1.11M Buy
209,900
+16,200
+8% +$81.5K ﹤0.01% 6947
2025
Q3 		$1.02M Buy
193,700
+73,700
+61% +$467K ﹤0.01% 7306
2025
Q2 		$682K Buy
120,000
+97,300
+429% +$554K ﹤0.01% 8432
2025
Q1 		$108K Buy
+22,700
New +$123K ﹤0.01% 11491
2024
Q4 		– Sell
-27,000
Closed -$171K – 12072
2024
Q3 		$171K Buy
27,000
+9,400
+53% +$49.1K ﹤0.01% 10617
2024
Q2 		$74.6K Buy
17,600
+4,100
+30% +$20.9K ﹤0.01% 11210
2024
Q1 		$97.9K Sell
13,500
-22,100
-62% -$140K ﹤0.01% 11231
2023
Q4 		$178K Buy
+35,600
New +$157K ﹤0.01% 10798
2021
Q3 		– Sell
-736
Closed -$29K – 12640
2021
Q2 		$29K Sell
736
-1,380
-65% -$56.3K ﹤0.01% 12389
2021
Q1 		$99K Buy
2,116
+1,648
+352% +$90.8K ﹤0.01% 11865
2020
Q4 		$18K Buy
+468
New +$15.9K ﹤0.01% 10890
2020
Q3 		– Sell
-1,056
Closed -$77K – 10466
2020
Q2 		$77K Sell
1,056
-752
-42% -$52K ﹤0.01% 9609
2020
Q1 		$95K Buy
1,808
+576
+47% +$38.5K ﹤0.01% 9355
2019
Q4 		$101K Buy
1,232
+636
+107% +$44.9K ﹤0.01% 9134
2019
Q3 		$34K Buy
596
+156
+35% +$11.7K ﹤0.01% 9868
2019
Q2 		$53K Sell
440
-452
-51% -$75.8K ﹤0.01% 9827
2019
Q1 		$164K Sell
892
-1,484
-62% -$265K ﹤0.01% 7982
2018
Q4 		$424K Sell
2,376
-680
-22% -$148K ﹤0.01% 6345
2018
Q3 		$978K Sell
3,056
-4,020
-57% -$1.43M ﹤0.01% 5252
2018
Q2 		$2.83M Buy
7,076
+1,304
+23% +$570K ﹤0.01% 3467
2018
Q1 		$2.07M Sell
5,772
-2,652
-31% -$985K ﹤0.01% 3848
2017
Q4 		$3.34M Buy
8,424
+480
+6% +$199K ﹤0.01% 3070
2017
Q3 		$3.39M Buy
7,944
+7,352
+1,242% +$1.98M ﹤0.01% 3049
2017
Q2 		$95K Sell
592
-220
-27% -$30K ﹤0.01% 8707
2017
Q1 		$102K Sell
812
-276
-25% -$35.6K ﹤0.01% 8381
2016
Q4 		$132K Buy
+1,088
New +$170K ﹤0.01% 8937

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jeff Yass's ABEO Position: Q2 2026 in Review

Jeff Yass reduced its Abeona Therapeutics (ABEO) stake by 55% in Q2 2026, selling an estimated $1.31M and leaving 194,377 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #7731.

Jeff Yass first reported a position in ABEO in Q3 2016 and has held it in 28 quarters since. The position peaked at $3.7M in Q4 2025. 127 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • Jeff Yass held 194,377 shares of Abeona Therapeutics worth $1.2M as of Q2 2026.
  • Jeff Yass sold 237,993 Abeona Therapeutics shares in Q2 2026, an estimated $1.31M.
  • Abeona Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #7731 holding.
  • Jeff Yass first reported a position in Abeona Therapeutics in Q3 2016 and has held it in 28 quarters since.
  • Jeff Yass's Abeona Therapeutics position peaked at $3.7M in Q4 2025.
  • 127 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.